-
EP3442572
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3442572
| EP3442572 - COMBINATION THERAPY OF RAMUCIRUMAB AND ABEMACICLIB FOR USE IN TREATMENT OF MANTLE CELL LYMPHOMA [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 05.02.2021 Database last updated on 02.11.2024 | |
| Former | Examination is in progress Status updated on 26.05.2020 | ||
| Former | Request for examination was made Status updated on 18.01.2019 | ||
| Former | The international publication has been made Status updated on 20.10.2017 | ||
| Former | unknown Status updated on 04.05.2017 | Most recent event Tooltip | 05.02.2021 | Application deemed to be withdrawn | published on 10.03.2021 [2021/10] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2019/08] | Inventor(s) | 01 /
SCHADE, Andrew Edward c/o Eli Lilly and Company P.O. Box 6288 Indianapolis Indiana 46206-6288 / US | [2019/08] | Representative(s) | Smith, Andrew George, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2019/08] | Smith, Andrew George, et al Eli Lilly and Company Limited European Patent Operations Lilly Research Centre Erl Wood Manor Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 17719102.0 | 07.04.2017 | [2019/08] | WO2017US26536 | Priority number, date | US201662322973P | 15.04.2016 Original published format: US 201662322973 P | [2019/08] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2017180461 | Date: | 19.10.2017 | Language: | EN | [2017/42] | Type: | A1 Application with search report | No.: | EP3442572 | Date: | 20.02.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.10.2017 takes the place of the publication of the European patent application. | [2019/08] | Search report(s) | International search report - published on: | EP | 19.10.2017 | Classification | IPC: | A61K39/395, A61K31/506, C07D401/04, C07D235/08, C07K16/28, C07K16/30 | [2019/08] | CPC: |
A61K31/506 (EP,US);
A61K39/3955 (US);
A61K39/39541 (EP,US);
A61K45/06 (EP,US);
A61K9/0019 (EP,US);
A61P35/00 (EP,US);
C07K16/2863 (EP,US);
C07K16/3061 (EP,US);
A61K2039/505 (EP,US);
| C-Set: |
A61K31/506, A61K2300/00 (US,EP);
A61K39/39541, A61K2300/00 (EP,US) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/08] | Title | German: | KOMBINATIONSTHERAPIE AUS RAMUCIRUMAB UND ABEMACICLIB ZUR VERWENDUNG BEI DER BEHANDLUNG VON MANTELZELLLYMPHOM | [2019/08] | English: | COMBINATION THERAPY OF RAMUCIRUMAB AND ABEMACICLIB FOR USE IN TREATMENT OF MANTLE CELL LYMPHOMA | [2019/08] | French: | POLYTHÉRAPIE À BASE DE RAMUCIRUMAB ET D'ABÉMACILIB DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DU LYMPHOME À CELLULES DU MANTEAU | [2019/08] | Entry into regional phase | 15.11.2018 | National basic fee paid | 15.11.2018 | Designation fee(s) paid | 15.11.2018 | Examination fee paid | Examination procedure | 06.11.2018 | Amendment by applicant (claims and/or description) | 15.11.2018 | Examination requested [2019/08] | 15.11.2018 | Date on which the examining division has become responsible | 29.05.2020 | Despatch of a communication from the examining division (Time limit: M04) | 09.10.2020 | Application deemed to be withdrawn, date of legal effect [2021/10] | 29.10.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/10] | Fees paid | Renewal fee | 30.04.2019 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 30.04.2020 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2015130540 (LILLY CO ELI [US]) [Y] 1-31 * the whole document *; | [Y] - CHAN YOON CHEAH ET AL, "Mantle Cell Lymphoma", JOURNAL OF CLINICAL ONCOLOGY, US, (20160410), vol. 34, no. 11, doi:10.1200/JCO.2015.63.5904, ISSN 0732-183X, pages 1256 - 1269, XP055375781 [Y] 1-31 * See paragraph "Agents in Development", Figure 2 * DOI: http://dx.doi.org/10.1200/JCO.2015.63.5904 | by applicant | WO03075840 | WO2005012359 | WO2010075074 | - L.D. BIGHLEY ET AL., Encyclopedia of Pharmaceutical Technology, (1995), pages 453 - 499 | - S.M. BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, (1977), vol. 66, page 1 | - BARRINGTON SF ET AL, "Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group", J CLIN ONCOL., (2014), vol. 32, no. 27, pages 3048 - 3058 | - CHESON BD ET AL, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification", J CLIN ONCOL., (2014), vol. 32, no. 27, pages 3059 - 3068 |